Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA accredits GS1, HIBCC for issuing device identifiers as UDI rule architect departs

This article was originally published in SRA

Executive Summary

The US Food and Drug Administration has accredited two global standards organizations, GS1 and the Health Industry Business Communications Council (HIBCC), for issuing unique device identifiers to support the implementation of the agency's new UDI regulations1,2. Separately, Jay Crowley, who was instrumental in authoring the FDA's UDI rule, is leaving the agency to join private consultancy firm USDM Life Sciences3.

You may also be interested in...

New Draft Guidance From FDA Paints Way Forward For Unique Device Identifiers

US FDA lays out for manufacturers how they should cobble together Unique Device Identifiers in a 10-page July 25 draft guidance. The document is intended to be a handy manual for firms as they work to meet UDI requirements and deadlines set by the agency.

EMA Set To Discuss Safety Of Ranitidine Drugs Soon

Following the announcement in the US that ranitidine drugs must be withdrawn from the market, the European Medicines Agency told the Pink Sheet it would decide on the fate of these medicines in the EU after wrapping up its own inquiry.

EU Pharma Urges Rethink On Knee-Jerk Trade Policies In Global COVID-19 Fight

EU drug industry federation, EFPIA, is concerned that an increase in protectionist trade measures by some countries could result in tit-for-tat policies that could hamper the global response to contain COVID-19.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts